Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab N01 plus irinotecan-based chemotherapy in RAS wild-type MSS/pMMR advanced colorectal cancer
ChiCTR2600130520Phase 4Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pertuzumab in colorectal cancer (CRC), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pertuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600130520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130520.